These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 16258090

  • 1. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
    Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ.
    J Clin Oncol; 2005 Nov 01; 23(31):7904-10. PubMed ID: 16258090
    [Abstract] [Full Text] [Related]

  • 2. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ, Hernandez-McClain J, Henary H.
    Am J Clin Oncol; 2008 Dec 01; 31(6):532-8. PubMed ID: 19060583
    [Abstract] [Full Text] [Related]

  • 3. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy.
    Gunawardana DH, Lichtenstein M, Better N, Rosenthal M.
    Clin Nucl Med; 2004 Feb 01; 29(2):81-5. PubMed ID: 14734902
    [Abstract] [Full Text] [Related]

  • 4. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD, Crook JM, Lukka H.
    Cancer Prev Control; 1998 Apr 01; 2(2):79-87. PubMed ID: 9765768
    [Abstract] [Full Text] [Related]

  • 5. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
    Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR.
    Clin Cancer Res; 2006 Mar 01; 12(5):1556-63. PubMed ID: 16533781
    [Abstract] [Full Text] [Related]

  • 6. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL.
    J Nucl Med; 2002 Jan 01; 43(1):79-86. PubMed ID: 11801708
    [Abstract] [Full Text] [Related]

  • 7. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM.
    Cancer; 2006 Sep 01; 107(5):1093-100. PubMed ID: 16888761
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
    Nilsson S, Strang P, Ginman C, Zimmermann R, Edgren M, Nordström B, Ryberg M, Kälkner KM, Westlin JE.
    J Pain Symptom Manage; 2005 Apr 01; 29(4):352-7. PubMed ID: 15857738
    [Abstract] [Full Text] [Related]

  • 10. Bone pain palliation with 85Sr therapy.
    Giammarile F, Mognetti T, Blondet C, Desuzinges C, Chauvot P.
    J Nucl Med; 1999 Apr 01; 40(4):585-90. PubMed ID: 10210217
    [Abstract] [Full Text] [Related]

  • 11. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
    Porter AT, McEwan AJ.
    Semin Oncol; 1993 Jun 01; 20(3 Suppl 2):38-43. PubMed ID: 7684865
    [Abstract] [Full Text] [Related]

  • 12. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M, Buchali K, Pink V, Lips H.
    Nuklearmedizin; 1992 Mar 01; 31(2):48-52. PubMed ID: 1373485
    [Abstract] [Full Text] [Related]

  • 13. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB, Yan WL, Dai JC, Xu F, Yuan Q, Shi HH.
    Zhonghua Nan Ke Xue; 2008 Sep 01; 14(9):819-22. PubMed ID: 18998467
    [Abstract] [Full Text] [Related]

  • 14. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W, Nakabayashi M, Regan MM, Oh WK.
    Cancer; 2007 Dec 15; 110(12):2709-15. PubMed ID: 17960608
    [Abstract] [Full Text] [Related]

  • 15. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
    El Demery M, Pouessel D, Avancès C, Iborra F, Rebillard X, Faix A, Ségui B, Delbos O, Ayuso D, Culine S.
    Prog Urol; 2006 Jun 15; 16(3):320-3. PubMed ID: 16821344
    [Abstract] [Full Text] [Related]

  • 16. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE.
    J Natl Cancer Inst; 2007 Nov 07; 99(21):1613-22. PubMed ID: 17971530
    [Abstract] [Full Text] [Related]

  • 17. [Combined treatment for pain from bone metastases in patients with prostate cancer].
    Ren X, Ying J, Yao D, Ye C, Jiang Y.
    Zhonghua Nan Ke Xue; 2004 Mar 07; 10(3):188-90. PubMed ID: 15080063
    [Abstract] [Full Text] [Related]

  • 18. [Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].
    Ouyang W, Liu JH, Liu WY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar 07; 27(3):390-1. PubMed ID: 17426002
    [Abstract] [Full Text] [Related]

  • 19. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ.
    J Nucl Med; 1997 Aug 07; 38(8):1175-9. PubMed ID: 9255144
    [Abstract] [Full Text] [Related]

  • 20. Sarcoma of the prostate: a single institutional review.
    Janet NL, May AW, Akins RS.
    Am J Clin Oncol; 2009 Feb 07; 32(1):27-9. PubMed ID: 19194120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.